In the Sweet Spot · October 5, 2026 · Novo Nordisk (NVO) · Healthcare

Novo Nordisk: a Triple Play name sitting near its 52-week low

Novo Nordisk pairs a 15.8% PAR and a Triple Play flag with a core score of 279, while trading about 6% above its 52-week low after a rough year.

Novo Nordisk (NVO) was Manifest Investing's In the Sweet Spot daily stock pick for October 5, 2026. At the time of the pick, Novo Nordisk carried a quality percentile of 86 and a projected annual return (PAR) of 15.8% against a MIPAR of 9.9%, placing it inside the sweet spot of 14.9% to 19.9%.

Key metrics at the time of the pick

Quality percentile: 86
Projected annual return (PAR): 15.8%
MIPAR (median PAR of coverage): 9.9%
PROVE: 14.9%
Core score (of 300): 279
Financial strength (of 100): 97
EPS stability (of 100): 96.1
Sales growth forecast: 7.0%
P/E ratio: 13.5
Price at pick: $37.32
52-week low: $35.12
52-week high: $64.16
Above 52-week low: 6.3%
Below 52-week high: 41.8%
Dividend yield: 4.7%
Projected yield: 2.4%
In the sweet spot: Yes
Triple play: Yes

Educational research, not advice. No position is taken and nothing is bought on anyone’s behalf.

Novo Nordisk (NVO) sits in the sweet spot today. Our PAR (Projected Annual Return, a five-year estimate of annualized total return) is 15.8%. With MIPAR (the median PAR across the stocks we follow) at 9.9%, the sweet spot runs from 14.9% to 19.9%, and NVO is inside that band. The 15.8% is not hugging an edge. It is also a full-coverage name, so the PAR comes from Mark’s analyst file.

What the numbers say

Quality: 85.7. This is a percentile rank against every company in our database, and above 80 is what we call excellent.
Financial strength: 97.1 out of 100. EPS stability is 96.1 out of 100, which means very smooth earnings per share history.
Core score: 279 out of 300. That is quality plus financial strength plus EPS stability, and 225 or more marks a core-holding candidate.
Growth forecast: 7.0% a year in sales.
Yield: the current yield is 4.69% and the projected yield is 2.4%.
Triple Play: NVO is flagged. George Nicholson’s idea is an elevated PAR (a depressed price), room for the P/E to expand, and room for profit margins to widen from today’s level. Mark hand-flags these in the analyst file, and NVO currently carries the flag.

Why today

The price is $37.32, only 6.3% above its 52-week low of $35.12 and 41.8% below the 52-week high of $64.16. PAR moves inversely to price, so much of that 15.8% reflects how far the shares have fallen. A large drop can also reflect real problems, so we try to understand why it happened.

Two news items frame the setting. On October 2, Novo said the FDA extended its review of denecimig, its hemophilia A drug, because of remediation work at a manufacturing facility (Reuters; company release). Motley Fool also reported that Novo has struck two licensing deals to widen its obesity pipeline (Motley Fool). CNBC covers how both Novo and Lilly are developing amylin-based drugs as a next step beyond GLP-1s (CNBC). The next earnings report is scheduled for November 4, 2026.

What our AI review of its earnings calls found

Our AI review of the recent calls covers Q3 2025 through Q1 2026. It was generated August 5, 2026, so it predates the Q2 call.

Overall trend: it rates the trend as slightly down.
The case for a trough: management raised guidance for the first time in over a year, and the new Wegovy pill launch is tracking well. A higher-dose Wegovy has narrowed the efficacy gap with its main rival, and the pipeline is maturing.
Red flags: the review names falling gross margin and structural U.S. pricing pressure, including the Most-Favored-Nations agreement with the administration. It also notes that management has chosen to reinvest cost savings rather than expand margins in the near term.
Open questions: competition from Lilly’s oral GLP-1, generic semaglutide in international markets, and how much the pill cannibalizes injectables.

How we weigh it

The Triple Play flag means the analyst file expects margins to be higher than today’s level in the long run. Whether that happens depends on the pricing and competition issues above. The data does not settle that question.

For outside context, the Wall Street consensus 12-month price target, per our data aggregator, is $44.67. That is a one-year figure from a different source and is not comparable to our five-year PAR.

The setup is a high core score, a Triple Play flag and a PAR in the band, alongside real business uncertainty. Probabilities, not promises, are the right frame here.

Sources

About In the Sweet Spot

Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse every pick in the archive.

In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date.